Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Short-term Investments (2021 - 2025)

Historic Short-term Investments for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $118.8 million.

  • Amylyx Pharmaceuticals' Short-term Investments fell 2691.01% to $118.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year decrease of 2691.01%. This contributed to the annual value of $99.1 million for FY2024, which is 5073.1% down from last year.
  • Amylyx Pharmaceuticals' Short-term Investments amounted to $118.8 million in Q3 2025, which was down 2691.01% from $122.7 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Short-term Investments high stood at $284.4 million for Q4 2022, and its period low was $45.9 million during Q4 2021.
  • For the 5-year period, Amylyx Pharmaceuticals' Short-term Investments averaged around $157.2 million, with its median value being $144.6 million (2022).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Short-term Investments surged by 51928.5% in 2022 and then plummeted by 5073.1% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Short-term Investments (Quarter) stood at $45.9 million in 2021, then soared by 519.28% to $284.4 million in 2022, then fell by 29.27% to $201.2 million in 2023, then tumbled by 50.73% to $99.1 million in 2024, then increased by 19.88% to $118.8 million in 2025.
  • Its Short-term Investments stands at $118.8 million for Q3 2025, versus $122.7 million for Q2 2025 and $144.3 million for Q1 2025.